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Regenerative medicine is transitioning into clinical programs utilizing stem/progenitor cell
therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that
share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary
glands: they are precursors to hepatic stem/progenitors in canals of Hering and to committed
progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis
within bile duct walls and a proximal-to-distal axis starting at the duodenum and ending with
mature cells in the liver or pancreas.
Clinical trials have been ongoing for years assessing effects of fetal-liver-derived hepatic stem/
progenitors transplanted into the hepatic artery of patients with various liver diseases.
Immunosuppression was not required. Control subjects, those given standard of care for a given
condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with
100–150 million hepatic stem/progenitor cells had improved liver functions and survival
extending for several years. Full evaluations of safety and efficacy of transplants are still in
progress. Determined stem cell therapies for diabetes utilizing hBTSCs remain to be explored but
are likely to occur following ongoing preclinical studies.
In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used
for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant
effects through paracrine signaling of trophic and immune-modulatory factors, and there is limited
evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs’ effects
are primarily via modulation of immune mechanisms.
Introduction
Stem cell therapies for diseased solid organs are an important potential modality of
regenerative medicine. In this review we focus on prospects for such therapies for liver and
pancreas utilizing determined stem cell subpopulations giving rise to these organs1–6, In
addition, mesenchymal stem cells (MSCs) and/or hematopoietic stem cells (HSCs) are being
used for patients with either liver diseases or with diabetes7–14. Stem cell therapies for liver
conditions are being used for acute liver failure, fulminant hepatitis, inborn errors of
metabolism, hepatitis viruses, liver toxins, alcohol consumption, autoimmunity and
metabolic disorders such as non-alcoholic steato-hepatitis (NASH). Together, diabetes and
these liver diseases and conditions constitute a major medical burden, one being addressed
by clinical trials of cell therapies using stem cells or mature cells, and that collectively
indicate a promising future of regenerative medicine strategies for these patients15–18.
Categories of Stem Cells giving Rise to Liver and Pancreas
Stem cells and their descendants, committed progenitors, are capable of sustained
proliferation and differentiation into specialized cells19. The crucial defining distinction of
stem cells is their ability to self-renew, i.e. to maintain indefinitely a population with
identical properties through symmetric and asymmetric cell divisions20, 21. Progenitors play
a transitory role in amplification of a cell population during development or regeneration.
When the self-renewal capacity of precursors cannot be rigorously ascertained, or when both
stem cells and progenitors are involved in a biological process, investigators often use the
term stem/progenitor cells.
Stem cells in the first stages of developing mammalian embryos have the remarkable
capacity to produce all of the body’s cell types and are termed pluripotent22. Embryonic
stem (ES) cells can remain pluripotent during extensive expansion as established cell
lines23–26. The self-renewal potential of ES cells appears virtually unlimited, although the
accumulation of spontaneous mutations and chromosomal rearrangements eventually
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degrades their practical utility27. A remarkable finding, one with enormous implications for
regenerative medicine and human genetics, is that pluripotent stem cells similar to ES cells
can be generated through reprogramming of mature somatic cells by introduction of small
sets of defined genetic factors28, 29. These are termed induced pluripotent stem (iPS) cells.
In principal, ES and iPS cells are sources of stem cells to treat any tissue or organ.
Moreover, autologous therapies with iPS cells theoretically should not require immune
suppression30–32. However, clinical trials with ES and iPS cells face challenges due to the
tumorigenic potential of residual undifferentiated cells resulting from difficulties in their
lineage restriction to a desired adult fate. Such challenges have short-circuited clinical trials
as occurred for Geron (Menlo Park, CA)33, 34. In 2013 Geron officials transferred all cell
therapy programs to Biotime (Alameda, CA). ViaCyte (San Diego, CA) plans clinical trials
for diabetes using encapsulated cells to minimize tumorigenicity and immunogenicity but at
the expense of introducing an artificial barrier to physiological functioning35. Lineage
restriction of ES or iPS cells to a specific fate comes at a price: it requires weeks of
treatments with expensive soluble signals and matrix components, resulting in a formidable
economic challenge to the clinical uses of these stem cells. Apart from these major concerns
for the use of ES and iPS cells in cell therapy, the cells can still provide medical benefits by
enabling the creation of in vitro models of human disease to facilitate drug discovery36.
Determined stem cells, called “adult stem cells” by the lay press, occur in fetal and postnatal
tissues but are restricted to lineages defined by a germ layer (ectoderm, mesoderm or
endoderm)19. Determined stem cells for liver and pancreas comprise multiple
subpopulations of biliary tree stem cells (hBTSCs), found in peribiliary glands (PBGs)
throughout the biliary tree. These give rise to hepatic stem cells (hHpSCs) and hepatoblasts
(hHBs), found intrahepatically in or near the canals of Hering37–39. The hBTSCs are
precursors also to pancreatic stem cells (hPSCs) in the hepato-pancreatic common duct that
lineage restrict to committed progenitors in pancreatic duct glands (PDGs)4. These stem
cells can replenish mature cells lost through normal turnover or injury and disease. Their
proliferation and differentiation are regulated tightly to ensure life-long maintenance of
appropriate numbers of both stem/progenitors and mature cells. This regulation is controlled
by intrinsic genetic programs and by extrinsic cues from soluble signals working
synergistically with extracellular matrix components within the microenvironments of stem
cell niches40, 41. Signals in niches help to maintain stem cells in a quiescent state, designated
G042, with cycling occurring slowly except for physiological demands to replace mature
cells. Although often described as having lesser expansion capacity than ES or iPS cells,
hHpSCs and hBTSCs can self-renew extensively. They are easily isolated from normal
tissue of any age donors and can be cultured under wholly defined, serum-free conditions for
months with more than 25–30 population doublings within 8 weeks, and through more than
40 population doublings in ~12 weeks, corresponding to greater than one trillion-fold (1 ×
1012) potential expansion1, 4, 43, 44.
Studies by C. Habibullah and associates indicate that hHpSCs and their descendants, hHBs,
can be effective in treating patients with liver disease17, 45–47 when transplanted via the
hepatic artery. The safety and potential advantages of transplanting cells through the hepatic
artery was demonstrated in prior studies using bone marrow-derived stem cells48. Clinical
studies of hBTSCs have yet to occur, but preclinical research is ongoing, and clinical trials
are anticipated to occur within a few years.
Mesenchymal stem cells or MSCs can be isolated from tissues such as bone marrow,
adipose tissue, umbilical cord tissue or amniotic fluid11, 49. These cells can be found in the
perivascular compartment of most (all?) organs, including the liver50, 51. They can be
expanded ex vivo for multiple passages, but not indefinitely, in standard media
supplemented with serum, though serum-free formulations better suited for clinical
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applications have now been developed 52. MSCs can be efficiently lineage restricted to any
mesodermal fate (e.g. bone, cartilage, fat) but only inefficiently to endodermal or ectodermal
fates49, 53–56. MSCs can differentiate into immature hepatocyte-like or islet-like cells but
with such low efficiency that they are not a practical source for clinical products57, 58. The
demonstrated mechanism of actions of MSCs for liver or pancreatic diseases comprise
trophic or immune-modulatory regulation11, 54, 59–61. Paracrine effects of MSCs in
regeneration are widely recognized,60. Despite the extensive use of MSCs in research
models and clinical trials, significant ambiguity remains regarding their identity and the
specific factors most critical to their role in tissue repair and organogenesis62.
This review will focus on current clinical programs using determined stem cells, MSCs or
HSCs, and the findings from these compared to results with mature cells, hepatocytes for
liver or pancreatic islets for diabetes. Details of the clinical programs, summaries from
cryopreservation and grafting technologies, and a more extensive list of references are given
in the online supplement.
Embryonic Development of Liver and Pancreas
Definitive endoderm derives from ES cells through effects of a number of key transcription
factors, including Goosecoid, MIXL1, SMAD2/3, SOX 7, and SOX1763. During early
embryonic development, endoderm subsequently segregates into foregut (lung,
thyroid)64, 65, stomach66, mid-gut (pancreas, biliary tree and liver)67, and both foregut and
hindgut (intestine)68, through effects of specific combinations of transcription factors. Those
dictating the mid-gut organs include SOX9, SOX17, FOXA1/FOXA2, ONECUT2/OC-2
and others69–72.
Organogenesis of liver and pancreas occurs with outgrowths at anlage on either side of the
duodenum and extending and ramifying into the branching biliary tree structure. The ends of
the biliary tree engage in the cardiac mesenchyme to form liver 73 and retroperitoneally in
aorta-induced pancreatic mesenchyme to form pancreas74. The biliary tree branch closest to
the duodenum forms ventral pancreas; the next major branch forms the cystic duct extending
to form gallbladder; and the final branches within the liver form large intralobular bile ducts
(Figure 1A). On the other side, the anlage forms a duct that extends to form dorsal pancreas.
The formation of intestine incorporates a twisting motion that swings the ventral pancreas to
the other side where it merges with the dorsal pancreas to form the complete pancreatic
organ. The liver cannot swing to the opposite side, due to its size and connections into the
cardiac mesenchyme. As a result, the liver and the ventral pancreas share the hepato-
pancreatic common duct connecting to the duodenum at the major papilla (the ampulla of
Vater), while the dorsal pancreas connects to the duodenum via the accessory pancreatic
duct at the minor papilla (Figure 1B).
Organization of Stem Cell Niches for Liver and Pancreas
All tissues are comprised of maturational lineages of cells consisting of epithelial-
mesenchymal cell partnerships beginning with epithelial stem cells (e.g. hHpSCs) partnered
with mesenchymal stem/progenitors (e.g. angioblasts). These yield cellular descendants
maturing coordinately and generating epithelial-mesenchymal partners changing step-wise
with respect to their morphology, ploidy, growth potential, gene expression and other
phenotypic traits, and regulated via gradients of soluble signals and matrix components that
are defined in many regions of the lineages but only partially in the stem cell
niches43, 44, 75–77. That which is known is summarized in Tables S1 and S2.
Lineage tracing studies have been done by Lemaigre78, Furuyama79, Kawaguchi80 and
others demonstrating that a population of SOX9+ cells gives rise to liver, biliary tree and
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pancreas. Those of Swenson81 found that acinar cells derive from a single stem cell, whereas
islets derive from more than one81. Importantly, stem cells are found in postnatal liver43, 82
but are very rare in postnatal pancreas83–85. This paradox has been clarified recently with
the discovery that pancreatic stem cells are not in the pancreas but rather in the biliary tree,
particularly in the hepato-pancreatic common duct.4.
Regeneration of liver and pancreas derives, in part, from proliferation of mature cells83, 86
and, in part, from stem/progenitors6, 87–93. However, the limited proliferative ability of
mature parenchymal cells or islets implicates stem/progenitors as logical cell sources for
clinical studies. More detailed presentations on the phenotypic traits of the biliary tree,5
pancreas,4 and liver 18 have been given in prior publications. The net sum of the phenotypic
traits and activities of cells at the sequential maturational lineage stages yields the functions
of the composite tissue.
Stem/Progenitor Cell Niches
Stem cells and progenitor cells reside in discrete locations called niches, each with a unique
environment41(Figures 2–4). The niches for the mid-gut organs include: peribiliary glands
(PBGs) in the extrahepatic and intrahepatic biliary tree1, 2, 4, 39; the ductal plates in fetal and
neonatal livers37, 78; the canals of Hering, derived from ductal plates and found in pediatric
and adult livers37–39, 90, 94; and the pancreatic duct glands (PDGs), reservoirs of committed
progenitors4, 95–97. These niches form a network that is continuous throughout the biliary
tree. The network has anatomical connections from biliary tree directly into the canals of
Hering2, the site of intrahepatic stem cells, and to the PDGs, reservoirs of committed
progenitors within the pancreas4. In situ studies provide hints, but not yet proof, that the
network may begin with Brunner’s Glands (Carpino, Lanzoni, et al., unpublished data),
found uniquely in the duodenum between the portals to the dorsal pancreatic duct and the
hepato-pancreatic duct98 (Figure 4).
Characteristics of the Biliary Tree Stem Cells In Situ
Niches consists of PBGs found within bile duct walls (intramural glands) or tethered to the
surface of bile ducts (extramural glands) of the biliary tree99. PBGs occur in highest
frequencies at branching points of the biliary tree; the greatest numbers are present in the
hepato-pancreatic common duct and, secondarily, in the large intrahepatic bile ducts5. Other
than anatomical and histological findings from the pioneering studies of Nakanuma and
associates99–101, nothing is known of the roles of the extramural PBGs. Each PBG contains
a ring of cells at its perimeter and is replete with mucous production (PAS-positive material)
in its center. The cells in the ring are phenotypically homogeneous in the PBGs in some sites
(e.g. hepato-pancreatic common duct, large intrahepatic bile ducts) but are quite
heterogeneous in other sites (e.g. cystic duct, hilum, common duct)1, 2, 4. The variations in
phenotypic traits of the cells implicate maturational lineages for which there are two
axes2, 4, 6:
• A radial axis1, 4 starting with high numbers of primitive stem cells (characterized
by elevated expression of pluripotency genes, co-expression of transcription factors
relevant to both liver and pancreas, and expression of other stem cell markers)
located in PBGs near the fibromuscular layer in the interior of the bile ducts, and
ends with mature cells towards the bile duct lumens. The radial axis near the liver
yields mature parenchymal cells (Figure 3); that near the pancreas yields mature
pancreatic cells; and that in between yields mature biliary epithelial cells.
• A proximal-to-distal axis1, 2, 4, 5 starts with high numbers of primitive stem cells in
PBGs near the duodenum, and progresses along the length of the bile ducts to
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mature cells with proximity to liver or to cells with pancreatic markers when near
the pancreas (Figure 4;Table S2).
The PBGs throughout the biliary tree retain a portion of the cells (~2–4%) as stem cells until
the connection with the canals of Hering2, the sites with the highest oxygen levels in the
liver; presumably oxygen is a trigger for rapid maturation to adult parenchymal cells. In the
other direction, the PBGs within the hepato-pancreatic common duct connect directly into
the pancreatic duct glands (PDGs)4; strikingly and for unknown reasons, the stem cell
features are lost immediately upon transition into the pancreatic ducts such that only
committed progenitors seem to remain. It is assumed, but as yet unknown, whether the
maturational lineages involve migration of cells. The network provides a biological
framework for ongoing organogenesis of liver, biliary tree and pancreas throughout life.
Further details on the phenotypic traits support the interpretation of maturational lineages.
The stem cells near fibromuscular layers co-express endodermal transcription factors
essential for liver and pancreas formation (e.g. SOX9, SOX17, PDX1). They express
pluripotency genes (NANOG, OCT4, SOX2, KLF4), other stem cell markers (NCAM,
CD133, CXCR4, SALL4), and indicators of proliferation (e.g. Ki67). They do not express
markers of mature cells (e.g. insulin, albumin)2, 102.
The first intermediate stages activate first expression of leucine-rich repeat-containing G
protein coupled receptor 5 (LGR5) and then epithelial cell adhesion molecule (EpCAM).
Subsequent stages involve retention of key endodermal transcription factors (e.g. PDX1 or
SOX17, but not both) in the nucleus. With increasing proximity to the bile duct lumen and
also in proximity to either liver or to pancreas, the expression of pluripotency genes fades
away; other stem cell traits are progressively lost (e.g. LGR5 or CD133 or SALL4); and
mature markers increase (e.g. albumin or insulin—which one depends on proximity to liver
or to pancreas, respectively). Huch et al 91, also found evidence for LGR5 expression on
hepatic stem cells; expansion of LGR5+ cells ex vivo with an agonist, R-spondin, and the
transplantation in vivo resulted in formation of liver and bile duct tissue.
In summary, stem cells and progenitors in the biliary tree and their descendants mature
along pathways defined embryologically and persisting throughout life in the form of
maturational lineages along a radial axis and a proximal (duodenum)-to-distal (organ) axis.
Future investigations must determine if the maturational axes are mediated by cellular
migration. A schematic of the proximal-to-distal axis is given in Figure 4 and further details
in Table S2.
Ex Vivo Studies of Hepatic and Biliary Tree Stem Cells
Isolation of hHpSCs and hHBs from livers of all donor ages can be performed by selection
for cells positive for expression of epithelial cell adhesion molecule, EpCAM43. EpCAM+
cells can be subdivided into hHpSCs by secondary selection for neural cell adhesion
molecule, NCAM (CD56) versus into hHBs by secondary selection for intercellular cell
adhesion molecule, ICAM-1 (CD54)82. The hHpSCs constitute approximately 1% (0.5% to
1.5%) of the total liver cell population throughout life in the livers of donors from fetuses to
elderly adults. The hHBs constitute more than 80% of the parenchyma in fetal livers
declining to 0.01% of the adult parenchyma. Unlike mature parenchymal cells, hHpSCs and
hHBs survive extended periods of ischemia, allowing collection even several days after
cardiac arrest103. The hHpSCs and hHBs express other stem/progenitor markers such as
CD133 (prominin), CD44 (hyaluronan receptors), aldehyde dehydrogenase (ALDH)104,
telomerase105, and hedgehog proteins75. They are small (hHpSCs=7–9 µm; hHBs=10–12
µm), less than half the size of mature parenchymal cells (diploid ones=18–22 µm), and
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express weak or negligible levels of adult liver-specific functions (e.g. albumin, cytochrome
P450s, or transferrin).
The hBTSCs are also tolerant of ischemia. Their concentration in biliary tree is higher than
that of hHpSCs and hHBs in liver. The PBGs in most biliary tree regions contain 2–4% stem
cells, and those in the hepato-pancreatic common duct are the richest of all with 5–9% stem
cells in the PBGs. Surface markers usable for immunoselection can be EpCAM or LGR5 for
some of them, but the majority are negative for EpCAM2, 4 and for LGR5 (Oikawa and
Reid, unpublished observations). Studies are ongoing to assess the efficacy of
immunoselection for other surface markers (e.g. NCAM, CD44).
The hHpSCs, hBTSCs, hHBs and committed hepatic and pancreatic progenitors can be
isolated also by culture selection in Kubota’s Medium106, a serum-free medium formulation
tailored for endodermal stem/progenitors and their mesenchymal stem/progenitor cell
partners1, 43, 44, 106, 107. It is comprised of any rich basal medium with low calcium (~0.3
mM), no copper, selenium (10−10M), zinc (10−12M), insulin (~5 µg/ml), transferrin/Fe (~5
µg/ml), high density lipoprotein (~10 µg/ml), and a defined mixture of purified free fatty
acids bound to highly purified albumin. Notably, the medium contains no cytokines or
growth factors. Mature cells do not survive in Kubota’s Medium; only stem/progenitors
survive44, 106. Given the focus of the review on clinical programs, a summary of culture
studies is not presented here but is available in various publications43, 44, 108, 109. Images of
cultures of hBTSCs and hHpSCs are provided in Figure 5.
Clinical Programs
The liver, biliary tree and pancreas are endodermal organs central to handling processing of
food, glycogen and lipid metabolism, detoxification of xenobiotics, regulation of energy
needs, and synthesis of diverse factors ranging from digestive enzymes (e.g. amylase,
trypsin), endocrine signals (e.g. insulin, glucagon), coagulation proteins to carrier proteins
(e.g. AFP, albumin, transferrin). The integrity of the body depends heavily on liver, biliary
tree, and pancreatic functions, and failure in any of them, especially the liver, results in rapid
death.
Clinical Programs in Cell Therapies for Liver (Table 1)
The only curative treatment for advanced liver disease is liver transplantation. However, this
treatment is limited by severe shortage of donor organs, the physical demands of the
complicated surgery, risks of severe complications, and high costs (typically ~$150,000 to
$180,000 for transplant and first year medical follow-up). These limitations drive interests to
explore cell therapies using transplantation of mature hepatocytes, MSCs or determined
stem cells. Those on transplantation with mature hepatocytes are presented in the online
supplement.
Determined Stem Cells—The only trials completed with transplants of determined stem
cells have been those conducted by Drs. Habibullah, Habeeb and their associates at the Liver
Institute in Hyderabad, India17, 45–47, 110, 111. These investigators focused on patients with
biliary atresia, inborn errors of metabolism (Crigler-Najjar), non-alcoholic steatohepatitis
(NASH), viral cirrhosis (HCV, HBV), alcoholic cirrhosis, and drug toxicity. Each year,
approximately 150,000 patients die of liver cirrhosis in India. Patients with advanced stages
of liver disease and very high MELD scores were candidates for this cell therapy program.
To date, more than 280 patients have been enrolled, but the findings from most of these
studies are not yet published.
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It was learned that for stem cell populations, it was preferable to transplant via the hepatic
artery, a strategy proved safe in preliminary studies with transplantation of bone marrow-
derived cells48. When done with EpCAM+ cells, it resulted in up to ~20–30%
engraftment17, 46, 47, 111. This procedure proved safe, as assessed by ultrasound indicating a
persistence of echotexture, no focal lesions, and without abnormal changes in the size of the
hepatic artery. Fetal liver-derived EpCAM+ cells (hHpSCs and hHBs) were marked with
Tc99m-Hexamethylpropyleneamine Oxime and injected; most of the marked cells remained
within the liver lobe injected. Also, most of the patients had grade 2 to grade 3 esophageal
varices before the transplants, and the majority showed reduction in the varices grading from
3 to 1. Because 2–3 months were required to observe effectiveness of transplants, patients
near death were not considered as candidates. A requirement for all trials was a life
expectancy of ~5–6 months. Remarkably, immune suppression was not required, although
donors and recipients were not matched for histocompatibility antigens. These early studies
have been published17, 45–47, 111. A representative early publication concerned a trial of 25
subjects and 25 controls with decompensated liver cirrhosis due to various causes. Subjects
received fetal liver-derived EpCAM+ cell infusions into the liver via the hepatic artery. At a
6-month follow-up, multiple diagnostic and biochemical parameters showed clear
improvement, and there was a significant decrease (p < 0.01) in the mean MELD scores.
The clinical trials were completed in June, 2012, and the results were used to apply for
regulatory approval in India. The application remains under review. Details on the long-term
outcomes of these patients are not yet available, and, of course, these publications are
needed to clarify the potential merits of these strategies. Validation of these early findings
with many more studies is needed to clarify the efficacy of such treatments for dysfunctional
liver conditions.
Clinical use of determined stem cells has been done thus far with freshly isolated, minimally
manipulated cells; in the future it is likely to be facilitated by large-scale manufacturing of
cell populations that will require assessment of their genetic stability. The sourcing of donor
cells may be fetal tissues in countries that permit their use. Although stem/progenitors cells
can be isolated from pediatric and adult livers, the competition for these organs will preclude
them as a practical source. Alternatively, neonatal livers or neonatal or adult biliary tree
tissue can be used as sources. They have distinct advantages both ethically and practically.
The cells may be utilized directly as isolated or after expansion in culture (subject to
additional levels of regulatory review). Grafting strategies in which cells are transplanted as
a graft comprised of matrix components such as hyaluronans (discussed in the online
supplement) 112, 113 should greatly improve engraftment, minimize ectopic distribution of
cells, hasten integration into the tissue and improvement of liver functions. However,
grafting strategies have yet to be used with patients.
Even though immunological issues proved minimal in transplants of fetal liver-derived
EpCAM+ cells17, 46, 47, 111, it yet may be desirable to match HLA (major histocompatibility)
types of donors and recipients. Given sufficient expansion, it should be possible to bank
large numbers of cells from a modest number of carefully selected donors and achieve a
beneficial degree of HLA matching for the majority of recipients114.
Clinical trials now being organized in Europe and Asia will comprise one arm duplicating
the trials in India and another utilizing the new grafting strategies. The hope is to provide
faster responses in patients with fewer cells and with minimal concerns for ectopic cell
distribution.
Clinical Trials with MSCs and HSCs—Background on the field of MSCs is given in
the online supplement. The ease of sourcing of MSCs, cryopreservation of MSCs, and
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transplantation into patients has resulted in large numbers of clinical trials of MSCs
throughout the world. At present over 20 clinical trials have been published on the use of
MSCs for treatment of chronic liver diseases caused by hepatitis viruses, alcohol or drugs
(Tables S4 and S5; www.clinicaltrials.gov). Most of these are investigations with small
numbers of patients (typically under 10)). Thus, they are similar to the clinical trials of
hepatocyte transplantation in providing anecdotal evidence or evidence with minimal
possibility of statistically validated findings of the efficacy of the treatments. There are a
small number with larger patient populations such as one reported by Peng at al.115
(Clinical-Trials.gov: NCT00956891) involving 53 patients who underwent a single
transplantation with autologous MSCs by a vascular route via the peripheral vasculature, the
spleen or through the hepatic artery into the liver. The trials comprised treatments with:
a. unfractionated bone marrow or peripheral blood or used cytokines (e.g. G-CSF) to
mobilize cells in the bone marrow
b. immunoselected cell populations (CD34+ cells, CD133+ cells) from bone marrow
c. cultured MSCs or cultures treated with growth factors such as hepatocyte growth
factor (HGF), epidermal growth factor (EGF) or fibroblast growth factor (FGF).
Transplantations of any of these forms of MSCs or HSCs were found to be safe and
significantly improved the quality of life and liver functions. The patient responses occurred
within days to weeks, but long-term effects (more than a few months) were not observed.
The conclusions are that effects are due to trophic and immune-modulatory factors. Caution
and prudence are required to interpret the findings correctly, since most are uncontrolled
studies. Therefore, randomized controlled studies are necessary in the future for clarification
and validation of these therapies as treatments for liver disease.
Stem Cell Therapies for Patients with Diabetes (Table 2)
Pancreatic islet transplants, one of the oldest forms of cell therapies116–118, are used for
Type 1 diabetes (T1D). At this time, pancreatic islet transplantation is NOT an option for
patients with Type 2 Diabetes. Pancreatic islet β-cells are lost due to autoimmune attacks in
patients with T1D and are functionally impaired in a subset of patients with Type 2 diabetes
(T2D). Thus, replenishment of the β-cell mass represents a major goal of several cell-based
therapeutic approaches under development. Immune suppression and/or tolerance induction
are essential to protect transplanted islets or residual β-cells118, 119. Transplantation of islets
is effective at restoring normo-glycemia in patients with T1D120, achieving a marked
improvement in patients’ quality of life121, relieving symptoms of the disease for up to
several years,122 and slowing or preventing disease progression.123 A major challenge is the
scarcity of transplantable islets124 and their intrinsic variability with respect to islet yield,
quality and engraftment potential125.
Early phase clinical trials of stem cell therapies (www.clinicaltrials.gov) are underway for
the treatment of T1D and T2D, focused either on MSCs (Table S6), or hematopoietic stem
cells (HSCs, Table S7) or on novel stem cell-based approaches (Table S8). Hopes that
MSCs or HSCs might differentiate to β-cells have dimmed, since lineage restriction to
functional β-cells is extremely limited, if it occurs at all126. Positive effects proved due to
immune-modulatory or paracrine signaling mechanisms126. MSCs are endowed with a well-
characterized immune-suppressive potential with beneficial paracrine and anti-inflammatory
activities, and are able to inhibit the autoimmune aggression wreaking havoc on β-cells in
T1D. Moreover, they may limit allo-immunity against transplanted β-cells, facilitating
autologous regeneration by suppressing inflammation, limiting apoptosis and fibrosis, and
stimulating angiogenesis126–128
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The HSCs possess the ability to reconstitute the hematopoietic compartment, including the
immune system. In autologous settings and after partial myelo-ablation, they can “reboot”
and re-educate the immune system to a β-cell tolerant state. Further details on clinical trials
of HSCs, MSCs and platform strategies for diabetes are given in the Online Supplement.
The derivation of β-cells from ES or iPS cells is a focus of many investigations 117, 118, 120.
Human ES cells can mature into β-like islet cells, but they are not the same as normal
ones119. Limited reproducibility of the elaborate stepwise protocols with various matrix
components and cytokines on different human ES cell lines is still hindering the evaluation
of cell products but is approaching cGMP grade35, 119. As stated previously, the residual
tumorigenic potential of ES cell-derived islets and the question of phenotypic stability are
hampering translation of preclinical studies into clinical trials. The use of iPS cells for the
clinics faces similar hurdles and additional challenges, since iPS cells are derived typically
from non-endodermal tissues, the end products retain partial traits (“memory”) of their
ectodermal or mesodermal origins and they can also bear mutations present in the donor
sources 129, 130.
In contrast to the supportive roles played by MSCs and HSCs, and to the limitations still
extant for ES and iPS cells, determined stem cells offer straightforward potential for future
β-cell therapies for patients with diabetes. The in situ and ex vivo studies of maturational
lineages provided evidence of progressive maturation of hBTSCs in PBGs to cells that are
NGN3+, PDX1+ committed endocrine progenitors, found in PDGs, and thence to insulin+ β
cells4. Important advantages of hBTSCs are that they are determined stem cells already
programmed to lineage-restrict to a pancreatic fate, thus the maturation into islet cells occurs
more efficiently and glucose responsiveness can be reached in only 7–10 days in culture4.
Contrarily, this does not occur in cultures from ES or iPS cells: they require being
transplanted in vivo to develop glucose sensitivity119. In addition, the hBTSCs can be
obtained from an ethically acceptable source, the biliary tree. Preclinical studies are still
required to define the yield from biliary tree tissue and to understand the cell doses required
for efficacy.
A major concern in applications of islet transplantation is the need of immunosuppression,
required to prevent transplant rejection and recurrence of autoimmunity (in the case of T1D)
and with possible negative impact on the recipient’s health131. We don`t know if hBTSC
cell therapy will require immunosuppression, but it might be minimal given that
immunosuppression proved unnecessary with fetal liver-derived EpCAM+ cells111.
A major reservoir of hBTSCs is in the hepato-pancreatic common duct4 implicating this site
as a logical target for transplantation in stem cell therapies for diabetes (Figure S3). This
could overcome the existing strategy of using ectopic sites for transplantation of pancreatic
precursors in order to avoid handling the pancreas, which can result in pancreatitis. A
proposed strategy is to transplant hBTSCs by grafting strategies113 into or onto the hepato-
pancreatic duct wall. If done with freshly isolated hBTSCs purified by immunoselection
methods, then the procedure would transfer minimally manipulated cells by an homotopic
(same place) and homotypic (same cell type) transplantation procedure. This could ease
regulatory issues for future clinical trials. Surgical operations on the biliary tree require a
sound understanding of biliary tree and vascular anatomy and should be restricted to
specialized centers because of the risk of peri-operative complications. The experience from
biliary tract reconstruction suggests that end-to-end anastomosis of large ductal fragments
should be avoided, since strictures frequently occur due to a compromised blood supply and
potential tension on the repair132, 133. The transplantation could theoretically be performed
by laparoscopic or by endoscopic strategies ideal in establishing outpatient procedures
(Figure S3).
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Forms of cell therapies are being utilized for treatment of patients with liver diseases and
with diabetes. Cell therapies with mature cells (hepatocytes for liver; pancreatic islets for
diabetes) provide acute relief, but their effects are transient, cause complications in the
transplantation procedures and require immunosuppression. They are limited also by
problems in sourcing of cells and difficulties in cryopreservation.
MSCs are easily sourced, readily cryopreserved, and involve transplantation procedures with
minimal, if any, complications. They can offer months to years of alleviation of disease
conditions by means of immune-modulatory and paracrine signaling mechanisms but offer
evidence of only inefficient lineage restriction to mature hepatic parenchymal cells or β-
cells. HSCs are effective as treatments in diseases in which there are aberrations of immune
reactions. Again, the evidence indicates little hope for consistent ability to transdifferentiate
into mature hepatic or pancreatic cells.
The only determined stem cell trials to date have tested fetal liver-derived EpCAM+ cells:
they have been transplanted via the hepatic artery to achieve sufficient engraftment, and they
required a survival of the patient for at least 3 months to exert efficacy. Early experience
suggests that the therapies have the potential to offer significant benefit, enabling patients to
have additional years of life with higher quality of health due to significant improvements in
functions and without the need for ongoing immunosuppressive therapy. These therapies
promise to be cost effective and to address unmet medical needs for a variety of disease
states in patients of all ages and in various states of health.
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Abbreviations
The stem cell or progenitor cell populations are indicated by an acronym which is preceded





hBTSCs human biliary tree stem cells
CD133 prominin 1
CFTR Cystic fibrosis transmembrane conductance regulator
C-PEP C-peptide
CS-PG chondroitin sulfate proteoglycan
CXCR4 CXC-chemokine receptor 4
CYP450 Cytochrome p450s
DS-PG dermatan sulfate proteoglycan
EGF epidermal growth factor
EpCAM epithelial cell adhesion molecule
ES cells embryonic stem cells
FBS fetal bovine serum
FGF fibroblast growth factor
FOXA2 forkhead box a2
GAGs glycosaminoglycans
GCG Glucagon
GFAP glial fibrillary acidic protein
HA hyaluronan
hHB human hepatoblast
HDM serum-free, hormonally defined medium
HGF hepatocyte growth factor
hHpSC human hepatic stem cells
HNF hepatocyte nuclear factor
HP-PG heparin proteoglycan
HS-PG heparan sulfate proteoglycan
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ICAM1 intercellular adhesion molecule-1
INS insulin
iPS induced pluripotent stem cell
KRT cytokeratin
KM Kubota’s Medium
LGR5 leucine-rich repeat-containing G protein coupled receptor 5
MIXL-1 Mix paired-like homeobox gene (expressed in primitive streak in embryos)
MUC6 mucin 6, oligomeric mucus/gel-forming
NASH non-alcoholic steatohepatitis
NCAM neural cell adhesion molecule
NGN3 neurogenin 3
PBG peribiliary gland
PDG pancreatic duct gland
PDX1 pancreatic and duodenal homeobox 1
PROX1 Prospero homeobox protein 1
SALL4 Sal-like protein 4
SMAD homologs of the Drosophila protein, mothers against decapentaplegic
(MAD) and the Caenorhabditis elegans protein
SMA alpha-smooth muscle actin
SOX Sry-related HMG box
VEGF vascular endothelial cell growth factor
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Figure 1. A. Schematic of the biliary tree
The biliary tree connects the liver and the pancreas to the duodenum. The PBGs found
throughout the biliary tree are stem cell niches containing stem cells and progenitors and are
in especially high numbers at various branching points of the tree (blue stars). Ultimately
they connect into the intrahepatic stem cell niches and into the pancreatic duct glands, niches
of committed progenitors within the pancreas. Figure modified from one in Turner et al 18.
B. Schematic of the hepato-pancreatic common duct
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Figure 2. Stem/progenitor cell niches
A and B are peribiliary glands in human biliary tree tissue; sections are stained for SOX17
or PDX1. Note the heterogeneity of cells expressing PDX1 or SOX 17 in these PBGs.
Figure modified from one in Cardinale et al.1. C. Canals of Hering, stem cell niches for
hHpSCs in an adult livers. Figure from Zhang et al, 37. C1. Enlargement of C and with
labeling to show hHpSCs in the canals; hHBs tethered to the ends of the canals of Hering;
and hHBs connecting to hepatocytes. D. Pancreatic duct glands (PDGs) containing only
committed progenitors stained for SOX2 that is expressed in peribiliary glands but not in
pancreatic duct glands. Image is from Wang et al 4.
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Figure 3. Radial axis maturational lineage near liver
Evidence for a maturational lineage progressing from PBGs near the fibromuscular layer to
mature cells at the bile duct lumens. EpCAM is an intermediate marker and albumin a more
mature marker for the cells that are maturing towards a liver fate. This occurs in the portion
of the biliary tree closest to the liver. Figure reproduced from one in Cardinale et al.1.
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Figure 4. Schematic of the network of stem/progenitor cell niches
Schematic of the network of stem/progenitor cell niches from those in the biliary tree to ones
in liver and pancreas. Figure provides a few of the markers on subpopulations of stem cells
and progenitors in the proximal-to-distal axis (see Table S2 for more details).
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Figure 5. Cultures of human biliary tree stem Cells (hBTSCs) and hepatic stem cells (hHpSCs)
under self-replication conditions
A-D: Colonies of human biliary tree stem Cells (hBTSCs); E-F: Colonies of hepatic stem
cells (hHpSCs). The stem cells have been plated onto culture plastic and in serum-free
Kubota’s Medium, a medium designed for endodrmal stem cells and progenitors.
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Table 1
Conclusions Regarding Ongoing Clinical Trials of Cell Therapies for Liver Diseases and Dysfunctions Cells
used
Cells used Results
Adult Parenchymal Cells--Hepatocyte Transplants
(Table S3)
Cells derived from neonatal, pediatric or adult livers
Delivery by vascular route into portal vein
Number of patients/trial: see Table S3 in online supplement
Cell numbers tested: from a few hundred million to billions
Complications in transplant procedures included emboli formation
Engraftment efficiencies were typically ~20%. Remainder of the cells either died
or distributed
ectopically, particularly to the lungs. (unknown significance)
Immunosuppression required
Significant Improvement in measured liver functions (e.g. albumin)
Effects transient. Typically a few months (maximum =a few years) for patients
with inborn errors of
metabolism. Typically a few days to a few months for acute liver injuries.
Mesenchymal Stem Cells (MSCs) (Tables S4 and S5) Cells derived from bone marrow, adipose tissue or umbilical cord
Number of patients in each trial: ~10; a few up to 53 in the United States; larger
numbers of patients in
trials in China
Delivery by vascular route through peripheral vasculature, spleen, portal vein, or
hepatic artery
Few if any complications in the transplant procedures
Immunosuppression not required
Transient improvements in liver functions and, in the larger trials, in MELD or
Child-Pugh Scores
Hepatic Stem Cells (hHpSCs) and Hepatoblasts
(hHBs)—EpCAM+ cells
EpCAM+ cells from fetal livers (gestational ages of 16–22 weeks)
Number of patients in the trials: >280
Delivery via hepatic artery
Cell numbers tested ranged from ~100–150 million
No complications from transplant procedures




Significant improvement in MELD or Child-Pugh Scores and in all measures of
liver functions
Effects long-term (>4 years)
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Table 2
Conclusions Regarding Ongoing Clinical Trials of Cell Therapies for Diabetes Cells used
Cells used Results
Adult Beta Cells (Pancreatic islet Transplants) Islets isolated from the pancreas of adult cadaveric donors
Delivery by infusion into the portal vein, percutaneous or laparoscopic procedure
Number of patients: 677 registered in the Collaborative Islet Transplant Registry, CITR.
The vast
majority of the data collected in the Registry are provided by groups in North America and
Europe134
Number of islets transplanted: a minimum of 9000 Islet Equivalents per kilogram, results
usually in
insulin independence. Most patients receive 2 infusions from different cadaveric donors,
resulting in
about 900.000 Islet Equivalents per patient
Few complications in transplant procedures (2% of the patients experience acute bleeding
or portal
vein thrombosis) <http://www.citregistry.org
Location of transplanted islets: the liver
Immunosuppression required
Significant Improvement: up to 85% of patients remain insulin independent for ~1 year
after
transplantation; up to 44% remain insulin independent for more than 3 years. Enduring
long-term
effects: reduction of HbA1c and resolution of severe hypoglycemia
Effects are transient, the functions of the graft decline with time.
Mesenchymal Stem Cells (MSCs)
(Tables S6 and S8)
Cells derived from bone marrow, umbilical cord or adipose tissue
Number of patients in each trial: See Table S6
Delivery by vascular route through peripheral vasculature
Few if any complications in the transplant procedures
Immunosuppression not required
Modest improvement
Hematopoietic Stem Cells (HSCs)
(Tables S7 and S8)
Bone marrow derived
Number of patients in the trials: see Table S7
Delivery by vascular route
No complications from transplant procedures
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